Direct oral anticoagulants (DOACs)
Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfarin as first-line for AF and VTE — but plans commonly require warfarin trial first.
What this class is
Direct oral anticoagulants are oral medications that inhibit specific clotting factors (Xa or thrombin) without requiring INR monitoring. They've largely replaced warfarin as first-line therapy for stroke prevention in non-valvular atrial fibrillation and for treatment of venous thromboembolism. Each agent has specific dosing, renal-adjustment, and contraindication profile.
Representative drugs
- Apixaban (Eliquis)
- Rivaroxaban (Xarelto)
- Dabigatran (Pradaxa)
- Edoxaban (Savaysa)
Common denial patterns
- Step therapy requiring warfarin trial first
- Non-formulary for specific DOAC
- Quantity limits below FDA-labeled dosing
Clinical guidelines that win appeals
- AHA/ACC/HRS AF Guideline 2023
- ACC Expert Consensus on DOAC use
Frequently asked questions
What is direct oral anticoagulants (doacs)?
Direct oral anticoagulants are oral medications that inhibit specific clotting factors (Xa or thrombin) without requiring INR monitoring. They've largely replaced warfarin as first-line therapy for stroke prevention in non-valvular atrial fibrillation and for treatment of venous thromboembolism. Each agent has specific dosing, renal-adjustment, and contraindication profile.
What are the common denial patterns?
Step therapy requiring warfarin trial first; Non-formulary for specific DOAC; Quantity limits below FDA-labeled dosing.
Which clinical guidelines support appeals?
AHA/ACC/HRS AF Guideline 2023; ACC Expert Consensus on DOAC use.
Related
- Cardiology drugsPCSK9, Entresto, SGLT2, Vyndamax, Camzyos, Kerendia, Vascepa
- Vascular & endovascular — AAA, carotid, PAD, varicose veins, IVC filtersEVAR / open AAA, CEA / CAS, peripheral arterial disease endovascular, endovenous ablation (RFA / laser / sclerotherapy), IVC filters
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- GLP-1 receptor agonistsSemaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Sax
Appeal a direct oral anticoagulants (doacs) denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com